Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Paule, Bernard ^a,b   Bastien, Laurence ^b   Deslandes, Emmanuelle ^c   Cussenot, Olivier ^d   Podgorniak, Marie Pierre ^c   Allory, Yves ^b   Naïmi, Benyoussef ^a   Porcher, Raphael ^c   de la Taille, Alexandre ^b   Menashi, Suzanne ^e   Calvo, Fabien ^a,c,f   Mourah, Samia ^a,c  

^a INSERM   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; ISOPROTEIN; SUNITINIB; VASCULOTROPIN 121; VASCULOTROPIN 165; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MESSENGER RNA; PYRROLE DERIVATIVE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; METASTASIS; PRIMARY TUMOR; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY TUMOR; METABOLISM; PATHOLOGY; SOLUBILITY;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS; PROTEIN ISOFORMS; PYRROLES; RNA, MESSENGER; SOLUBILITY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956270281     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010715     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56: 106-130.
2. Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23: 1028-1043.
3. Amato RJ (2005) Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16: 7-15.
4. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9: 653-660.
5. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
8. Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, et al. (2008) Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 100: 1454-1463.
9. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, et al. (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26: 127-131.
10. Rixe O, Billemont B, Izzedine H (2007) Hypertension as a predictive factor of Sunitinib activity. Ann Oncol 18: 1117.
11. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, et al. (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27: 3312-3318.
12. Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, et al. (2009) Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 9: 82.
13. Loupakis F, Falcone A, Masi G, Fioravanti A, Kerbel RS, et al. (2007) Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol 25: 1816-1818.
14. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, et al. (2008) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26: 3743-3748.
15. Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, et al. (1994) Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54: 4233-4237.
16. Tomisawa M, Tokunaga T, Oshika Y, Tsuchida T, Fukushima Y, et al. (1999) Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer 35: 133-137.
17. Rivet J, Mourah S, Murata H, Mounier N, Pisonero H, et al. (2008) VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer 112: 433-442.
18. Tsuchiya N, Sato K, Akao T, Kakinuma H, Sasaki R, et al. (2001) Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma. Tohoku J Exp Med 195: 101-113